Aardvark Therapeutics’ (AARD) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research report sent to investors on Monday, Marketbeat reports.

Several other research firms also recently weighed in on AARD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Monday, December 29th. BTIG Research dropped their price target on shares of Aardvark Therapeutics from $26.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday. Oppenheimer started coverage on shares of Aardvark Therapeutics in a report on Tuesday, December 23rd. They issued an “outperform” rating and a $35.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Aardvark Therapeutics in a report on Friday, November 14th. Finally, Royal Bank Of Canada downgraded Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and cut their target price for the stock from $18.00 to $6.00 in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.09.

Aardvark Therapeutics Stock Performance

NASDAQ:AARD opened at $5.64 on Monday. Aardvark Therapeutics has a 1 year low of $4.74 and a 1 year high of $17.94. The stock has a market cap of $122.78 million and a price-to-earnings ratio of -2.66. The business has a fifty day moving average of $13.03 and a 200-day moving average of $12.06.

Insider Buying and Selling

In other Aardvark Therapeutics news, CFO Nelson Sun bought 3,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $14.40 per share, with a total value of $43,200.00. Following the completion of the purchase, the chief financial officer directly owned 108,484 shares in the company, valued at approximately $1,562,169.60. This trade represents a 2.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Tien-Li Lee bought 7,000 shares of Aardvark Therapeutics stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average price of $14.48 per share, with a total value of $101,360.00. Following the completion of the acquisition, the chief executive officer directly owned 1,551,613 shares of the company’s stock, valued at $22,467,356.24. This represents a 0.45% increase in their position. The SEC filing for this purchase provides additional information.

Institutional Investors Weigh In On Aardvark Therapeutics

Several large investors have recently modified their holdings of AARD. SymBiosis Capital Partners LLC acquired a new stake in shares of Aardvark Therapeutics during the fourth quarter worth $6,255,000. Millennium Management LLC purchased a new position in Aardvark Therapeutics in the 3rd quarter worth about $4,248,000. Cresset Asset Management LLC purchased a new position in Aardvark Therapeutics in the 3rd quarter worth about $1,951,000. Geode Capital Management LLC raised its holdings in Aardvark Therapeutics by 53.5% during the 4th quarter. Geode Capital Management LLC now owns 297,865 shares of the company’s stock worth $3,910,000 after buying an additional 103,830 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Aardvark Therapeutics by 20.6% during the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock valued at $7,386,000 after buying an additional 94,744 shares in the last quarter.

Trending Headlines about Aardvark Therapeutics

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: Technical/market reaction: The stock is rallying on heavy intraday volume and volatility, consistent with a short-covering/technical rebound after the steep drop earlier in the week. (No single article — market action/volume cited in trading summary)
• Neutral Sentiment: Short-interest reporting is inconsistent/erroneous in some feeds (reports showing 0 shares), so apparent “short interest” data should be treated with caution until reliable filings update.
• Neutral Sentiment: HC Wainwright reiterated a Neutral rating for AARD. HC Wainwright Reiterates Neutral Rating for Aardvark Therapeutics (NASDAQ:AARD)
• Neutral Sentiment: Morgan Stanley reiterated an Equal Weight rating. Morgan Stanley Reiterates Equal Weight Rating for Aardvark Therapeutics (NASDAQ:AARD)
• Neutral Sentiment: Stifel Nicolaus maintains a Hold rating. Aardvark Therapeutics (NASDAQ:AARD) Earns “Hold” Rating from Stifel Nicolaus
• Negative Sentiment: Clinical risk: Aardvark paused its Phase 3 HERO (Prader‑Willi syndrome/metabolic) trial because of cardiac safety observations — the primary driver of this week’s selloff and the main fundamental negative for the stock. Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions
• Negative Sentiment: Additional press coverage highlights the trial pause and market reaction (context on safety signals and share plunge). Aardvark pauses phase 3 metabolic drug study over cardiac observations
• Negative Sentiment: Legal risk: Multiple shareholder-investigations/class-action solicitations have been announced (Pomerantz, Schall), increasing potential litigation exposure and investor uncertainty. AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm INVESTOR-ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.
• Negative Sentiment: Analyst sentiment turned more cautious: BTIG cut its price target (to $9) and Oppenheimer issued a pessimistic forecast — pressure on near-term expectations and valuation. BTIG Research Lowers Aardvark Therapeutics (NASDAQ:AARD) Price Target to $9.00 Oppenheimer Issues Pessimistic Forecast for Aardvark Therapeutics (NASDAQ:AARD) Stock Price

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.